TY - JOUR
T1 - Trends in the prescribing of psychotropic medications to preschoolers
AU - Zito, Julie Magno
AU - Safer, Daniel J.
AU - DosReis, Susan
AU - Gardner, James F.
AU - Boles, Myde
AU - Lynch, Frances
PY - 2000/2/23
Y1 - 2000/2/23
N2 - Context: Recent reports on the use of psychotropic medications for preschool-aged children with behavioral and emotional disorders warrant further examination of trends in the type and extent of drug therapy and sociodemographic correlates. Objectives: To determine the prevalence of psychotropic medication use in preschool-aged youths and to show utilization trends across a 5-year span. Design: Ambulatory care prescription records from 2 state Medicaid programs and a salaried group-model health maintenance organization (HMO) were used to perform a population-based analysis of three 1-year cross-sectional data sets (for the years 1991, 1993, and 1995). Setting and Participants: From 1991 to 1995, the number of enrollees aged 2 through 4 years in a Midwestern state Medicaid (MWM) program ranged from 146 369 to 158 060; in a mid-Atlantic state Medicaid (MAM) program, from 34 842 to 54 237; and in an HMO setting in the Northwest, from 19 107 to 19 322. Main Outcome Measures: Total, age-specific, and gender-specific utilization prevalences per 1000 enrollees for 3 major psychotropic drug classes (stimulants, antidepressants, and neuroleptics) and 2 leading psychotherapeutic medications (methylphenidate and clonidine); rates of increased use of these drugs from 1991 to 1995, compared across the 3 sites. Results: The 1995 rank order of total prevalence in preschoolers (per 1000) in the MWM program was: stimulants (12.3),90% of which represents methylphenidate (11.1); antidepressants (3.2); clonidine (2.3); and neuroleptics (0.9). A similar rank order was observed for the MAM program, while the HMO had nearly 3 times more clonidine than antidepressant use (1.9 vs 0.7). Sizable increases in prevalence were noted between 1991 and 1995 across the 3 sites for clonidine, stimulants, and antidepressants, while neurolepticuse increased only slightly. Methylphenidate prevalence in 2- through 4-year-olds increased at each site: MWM, 3-fold; MAM, 1.7-fold; and HMO, 3.1-fold. Decreases occurred in the relative proportions of previously dominant psychotherapeutic agents in the stimulant and antidepressant classes, while increases occurred for newel less established agents. Conclusions: In all 3 data sources, psychotropic medications prescribed for pre-schoolers increased dramatically between 1991 and 1995. The predominance of medications with off-label (unlabeled) indications calls for prospective community-based, multidimensional outcome studies.
AB - Context: Recent reports on the use of psychotropic medications for preschool-aged children with behavioral and emotional disorders warrant further examination of trends in the type and extent of drug therapy and sociodemographic correlates. Objectives: To determine the prevalence of psychotropic medication use in preschool-aged youths and to show utilization trends across a 5-year span. Design: Ambulatory care prescription records from 2 state Medicaid programs and a salaried group-model health maintenance organization (HMO) were used to perform a population-based analysis of three 1-year cross-sectional data sets (for the years 1991, 1993, and 1995). Setting and Participants: From 1991 to 1995, the number of enrollees aged 2 through 4 years in a Midwestern state Medicaid (MWM) program ranged from 146 369 to 158 060; in a mid-Atlantic state Medicaid (MAM) program, from 34 842 to 54 237; and in an HMO setting in the Northwest, from 19 107 to 19 322. Main Outcome Measures: Total, age-specific, and gender-specific utilization prevalences per 1000 enrollees for 3 major psychotropic drug classes (stimulants, antidepressants, and neuroleptics) and 2 leading psychotherapeutic medications (methylphenidate and clonidine); rates of increased use of these drugs from 1991 to 1995, compared across the 3 sites. Results: The 1995 rank order of total prevalence in preschoolers (per 1000) in the MWM program was: stimulants (12.3),90% of which represents methylphenidate (11.1); antidepressants (3.2); clonidine (2.3); and neuroleptics (0.9). A similar rank order was observed for the MAM program, while the HMO had nearly 3 times more clonidine than antidepressant use (1.9 vs 0.7). Sizable increases in prevalence were noted between 1991 and 1995 across the 3 sites for clonidine, stimulants, and antidepressants, while neurolepticuse increased only slightly. Methylphenidate prevalence in 2- through 4-year-olds increased at each site: MWM, 3-fold; MAM, 1.7-fold; and HMO, 3.1-fold. Decreases occurred in the relative proportions of previously dominant psychotherapeutic agents in the stimulant and antidepressant classes, while increases occurred for newel less established agents. Conclusions: In all 3 data sources, psychotropic medications prescribed for pre-schoolers increased dramatically between 1991 and 1995. The predominance of medications with off-label (unlabeled) indications calls for prospective community-based, multidimensional outcome studies.
UR - http://www.scopus.com/inward/record.url?scp=0034704577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034704577&partnerID=8YFLogxK
U2 - 10.1001/jama.283.8.1025
DO - 10.1001/jama.283.8.1025
M3 - Article
C2 - 10697062
AN - SCOPUS:0034704577
SN - 0098-7484
VL - 283
SP - 1025
EP - 1030
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 8
ER -